Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1582-1585

  Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Atherosclerosis; Cardiovascular risk; Homocysteine

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; MULTIVITAMIN; PYRIDOXINE;

CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONFERENCE PAPER; DEATH; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; GRAIN; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; LOW DRUG DOSE; NORTH AMERICA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK REDUCTION; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

HUMANS; STROKE; VITAMINS;

EID: 36849007022     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.325     Document Type: Conference Paper

References (46)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Carson NE, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962;37:505-13.
3. Gerritsen T, Vaughn JG, Waisman HA. The identification of homocystine in the urine. Biochem Biophys Res Commun 1962;9:493-6.
4. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969;56:111-28.
5. Brattström L, Hardebo JE, Hultbert BL. Moderate hyperhomocyst(e) inemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984;15:1012-6.
6. Boers GH, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleiher WJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-14.
7. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
8. Graham IM, Daly L, Refsum H, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1997;277:1775-81.
9. Nygård O, Nordehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
10. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering plasma total homocysteine to prevent recurrent stroke, myocardial infarction, and death in ischemic stroke patients: results of the Vitamin Intervention for Stroke Prevention (VISP) randomized trial. J Am Med Assoc 2004;291:565-75.
11. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
12. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
13. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006;354:1629-32.
14. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Med Assoc 2006;296:2720-6.
15. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme A reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation 2002;105:1037-43.
16. Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res 2006;99:598-606.
17. Díaz DE Tuesta AM, Ribo MD, Belinchon O, Marchena PJ, Bruscas MJ, Val E, et al. Low levels of vitamin B12 and venous thromboembolic disease in elderly men. J Intern Med 2005;258:244-9.
18. Eichinger S. Are B vitamins a risk factor for venous thromboembolism? Yes. J Thromb Haemost 2006;4:307-8.
19. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003;102:1363-6.
20. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-6.
21. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:2479-83.
22. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004;109:369-74.
23. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-8.
24. Van den Berg M, Boers GH, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;25:176-81.
25. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
26. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996;54:1-30.
27. Barbato JC, Catanescu O, Murray K, DiBello PM, Jacobsen DW. Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler Thromb Vasc Biol 2007;27:49-54.
28. Colgan SM, Austin RC. Homocysteinylation of metallothionein impairs intracellular redox homeostasis: the enemy within! Arterioscler Thromb Vasc Biol 2007;27:8-11.
29. Zhou J, Moller J, Ritskes-Hoitinga M, Larsen ML, Austin RC, Falk E. Effects of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. Atherosclerosis 2003;168:255-62.
30. van Oort FV, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB, et al. Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study. Am J Clin Nutr 2003;77:1318-23.
31. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002;50:1789-95.
32. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol 1999;18:405-10.
33. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke 2005;36:2404-9.
34. Herzlich B, Herbert V. Depletion of serum holotranscobalamin II. An early sign of negative vitamin B12 balance. Lab Invest 1988;58:332-7.
35. Johnston CS, Thomas JA. Holotranscobalamin II levels in plasma are related to dementia in older people. J Am Geriatr Soc 1997;45:779-80.
36. Lindgren A, Kilander A, Bagge E, Nexo E. Holotranscobalamin - a sensitive marker of cobalamin malabsorption. Eur J Clin Invest 1999;29:321-9.
37. Clarke R, Sherliker P, Hin H, Nexo E, Hvas AM, Schneede J, et al. Detection of vitamin B12 deficiency in older people by measuring vitamin B12 or the active fraction of vitamin B12, holotranscobalamin. Clin Chem 2007;53:963-70.
38. Andres E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. Can Med Assoc J 2004;171:251-9.
39. Spence JD. Nutrition and stroke prevention. Stroke 2006;37:2430-5.
40. Quinn K, Basu TK. Folate and vitamin B12 status of the elderly. J Clin Nutr 1996;50:340-2.
41. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007. In press.
42. Poli D, Antonucci E, Cecchi E, Marcucci R, Liotta AA, Cellai AP, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 2005;36:2159-63.
43. Wang X, Qin X, Li H, Mao G, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
44. Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr 2003;133:4135-8.
45. Urquhart BL, Freeman DJ, Spence JD, House AA. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis 2007;49:109-17.
46. The VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 2004;13:120-6.